Kezar was testing the treatment, zetomipzomib, in patients with active lupus nephritis, a type of kidney disease caused by lupus - where the body's immune system attacks its own cells and organs.

(Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday. The FDA's decision comes after ...

The San Francisco-based company said it had informed the U.S. Food and Drug Administration and European regulators of the decision to pause enrollment and dosing in the trial. An independent study ...

Oct 4 (Reuters) - The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' (KZR.O), opens new tab trial of experimental drug for lupus, the company said on Friday.

shedding early gains made after the company and Belgian partner UCB announced positive results in a late-stage trial of a treatment for the chronic autoimmune disease lupus. The Phase 3 trial ...

Aurinia Pharmaceuticals said Japanese regulators have approved its drug voclosporin in a combination treatment for lupus. The company said Tuesday that the Japanese Ministry of Health, Labour ...

Kezar was testing the treatment, zetomipzomib, in patients with active lupus nephritis, a type of kidney disease caused by lupus — where the body’s immune system attacks its own cells and organs. To ...

New research is improving doctors’ understandings of how lupus hijacks the immune systems of patients and could lead to a new treatment that targets the pathways involved in the autoimmune disease.

Effective management of lupus requires a comprehensive approach, including regular medical check-ups, blood tests, and adherence to prescribed treatments. By addressing symptoms early and ...

New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However ...

Aurinia Pharma's LUPKYNIS is well-positioned to become a new standard of care. Read why I think AUPH stock is a strong buy.